<DOC>
	<DOCNO>NCT00679523</DOCNO>
	<brief_summary>The purpose study determine safety efficacy 5.0 % 7.5 % AN2690 Solution treatment distal , subungual onychomycosis great target toenail .</brief_summary>
	<brief_title>Safety Efficacy Study Subjects With Onychomycosis Great Toenail</brief_title>
	<detailed_description>The first group 30 protocol-qualified subject assign Treatment Group 1 give 5 % AN2690 Solution . Provided adequate evidence clinical safety two week dose 5 % AN2690 Solution , second group 30 protocol-qualified subject assign Treatment Group 2 give 7.5 % AN2690 Solution . A third group 30 subject enrol assigned high safe concentration AN2690 evaluate study .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tavaborole</mesh_term>
	<criteria>1 . Witnessed , sign informed consent approve Ethics Committee 2 . Male female subject race least 18 year age old 65 year age time screen 3 . Subjects diagnosis onychomycosis least one great toenail positive KOH wet mount nail 4 . Onychomycosis involve 2060 % affect great toenail determine visual inspection nail trim 5 . The combined thickness distal nail plate associate hyperkeratotic nail bed &lt; 3 mm 6 . Affected great toenail treat capable regrowth document history recent observation least 2 mm growth 7 . Normal clinically significant screen safety labs 1 . Females childbearing potential use highly effective method birth control ( e.g . implant , injectables , combine oral contraceptive , intrauterine contraceptive device ) study 2 . Diabetes mellitus require treatment diet exercise 3 . Subjects chronic moccasin type T. pedis 4 . Subjects history fail previous topical antifungal therapy onychomycosis 5 . Subjects unwilling refrain use nail cosmetic clear color nail lacquer screen visit end study . 6 . Subjects undergone specify washout period ( ) follow topical preparation subject require concurrent use follow topical medication : Topical antifungal apply foot ( include antifungal treatment T. pedis study ) : 4 week Antiinflammatories , corticosteroid , topical immunomodulators : 2 week 7 . Subjects undergone specify washout period ( ) follow systemic medication subject require concurrent use follow systemic medication : Corticosteroids ( include intramuscular injection ) : 2 week Antifungals treatment onychomycosis systemic antifungal know activity dermatophytes : 24 week Systemic immunomodulators : 4 week 8 . Treatment type cancer within last 6 month 9 . History significant internal disease 10 . Subjects medical history current past psoriasis skin and/or nail 11 . Concurrent lichen planus 12 . Subjects know allergic test product ( ) components test product ( ) history hypersensitivity allergic reaction study preparation describe Investigator 's Brochure 13 . Nail anatomic abnormality toe , e.g. , genetic nail disorder , primentary disorder , onychogryphosis , trauma nail ( ) treat 14 . AIDS AIDS relate complex 15 . History street drug alcohol abuse 16 . Any subject able meet study attendance requirement 17 . Subjects participate trial investigational drug device within 60 day prior enrollment participation research study concurrent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Onychomycosis</keyword>
	<keyword>Fungal Nail</keyword>
</DOC>